Commentary - Journal of Cellular Immunology (2021) Volume 3, Issue 3
Efferocytosis and Anthrax: Implications for Bacterial Sepsis?
Joshua S. Mytych1,2*, Zijian Pan1, A. Darise Farris1,2
1Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation (OMRF), 825 NE 13th St., Oklahoma City,
OK 73104, USA
2Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center (OUHSC), 940 Stanton L. Young
Blvd, Oklahoma City, OK 73104, USA
- *Corresponding Author:
- Joshua S. Mytych
Received date: January 16, 2021; Accepted date: April 09, 2021
Citation: Mytych JS, Pan Z, Farris AD. Efferocytosis and Anthrax: Implications for Bacterial Sepsis?. J Cell Immunol. 2021; 3(3):
Copyright: © 2021 Mytych JS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Efferocytosis, Bacillus anthracis, Sepsis,
Apoptotic cell clearance, Edema toxin
Bacillus anthracis (Ba) is a gram-positive, rod-shaped, spore- and toxin-forming bacterium. While mainly an herbivore pathogen, human infection with Ba spores can occur through a number of routes including cutaneous, gastrointestinal, injectional, or inhalational . The deadliest form of anthrax exposure is through inhalation of Ba spores, leading to systemic dissemination of the bacteria, with mortality ranging from 45% to 90% [2,3]. Current evidence suggests that sepsis, defined as a lifethreatening organ dysfunction caused by a dysregulated host response to infection , is likely to play a critical role
in death from systemic anthrax .
Significant increases in leukocyte apoptosis in the innate and adaptive lineages including natural killer, dendritic, T, and B cells, as well as monocytes and macrophages are known to accompany sepsis infections though the mechanisms leading to immune cell apoptosis are not well-characterized . Although a primary role for Ba Lethal Toxin (LT) in killing human immune cells was long-suspected, several subsequent studies have failed to convincingly demonstrate LT’s capacity to kill most types of human leukocytes in vitro [7-11]. A recent review highlighted potential alternative mechanisms of elevated immune cell death in the setting of sepsis, including increases in cytokines, steroids, or host damage-associated molecular patterns (DAMPs), as well as changes in cell survival and death pathways for Fas signaling . Regardless of the mechanisms responsible for immune cell death in late-stage anthrax and sepsis,
the resulting cellular corpses must be efficiently cleared
to prevent the propagation of inflammation. Release of
normally sequestered host cell DAMPs can arise from
improper clearance of apoptotic cells as a consequence of
the progression of apoptosis to later stages of cell death.
Secondary necrosis is a late-stage process whereby the
cell membrane permeabilizes, leading to the release of
intracellular contents including cytosolic and nuclear
proteins (e.g. HMGB-1, nucleosomes, etc.) that promote
inflammation after their recognition by various pattern
recognition receptors [13,14]. Thus, a growing interest
has developed around the mechanisms, consequences and
interventions of clearing apoptotic cells during sepsis and
systemic anthrax infection.
In our recent publication, we found that Ba Edema Toxin (ET) inhibits the proper clearance of apoptotic neutrophils by human macrophages. Ba’s virulence factors include its outer poly-D glutamic acid capsule, pathogen-associated molecular patterns (PAMPs) including peptidoglycan, lipoteichoic acid and nucleic acids, as well as two A-B type toxins: LT and ET. ET is composed of Protective Antigen (PA) and Edema Factor (EF), and acts to increase cyclic adenosine monophosphate (cAMP) to supra-physiologic levels, while LT is a metalloprotease composed of PA + Lethal Factor (LF) and acts to degrade MAPK signaling intermediates . PA is the cell-binding component of both ET and LT that is required for entry of the toxins into host cells, as well as translocation of the toxins from the endosome into the cytosol of target cells. The toxins act to stunt the initial immune response, allowing bacteria to reach high numbers . ET modulates responding
macrophages by suppressing phagocytosis , chemotaxis , and as our recent publication showed, the clearance
of apoptotic cells. How bacterial components affect the
clearance of apoptotic cells during sepsis or systemic
anthrax infection is currently not well characterized.
Clearance of Apoptotic Cells – Efferocytosis
Efferocytosis is the process by which phagocytes recognize, ingest, and respond to apoptotic cells. This process typically maintains tissue homeostasis; however, defects in efferocytosis are linked to autoimmune disease , tissue injury , and impaired resolution of inflammation . Efferocytosis is a multi-stage process that begins with the initial recognition of apoptotic cells, which occurs through either binding of macrophage receptors to the apoptotic membrane (direct recognition) or through soluble mediators that bridge macrophage receptors to the apoptotic membrane (indirect recognition). After initial binding, apoptotic cells are ingested by a coordinated, Rac1-dependent process that clears the cellular debris, and following processing, macrophages undergo phenotypic changes at the transcriptional level to modulate macrophage response (reviewed in ). Physiologic clearance of sudden increases in apoptotic cells, relevant to sepsis, is thought to be mediated by a combination of lymphoid organ and tissue-resident macrophages [23,24]. Efferocytic macrophages in humans exhibit high expression of CD163, CD206, MerTK, and other proefferocytic markers . In vitro these cells are often modeled by polarizing macrophages through exposure to glucocorticoids (e.g. dexamethasone) or a combination of cytokines (e.g. IL-4 and IL-13, or IL-10) . Interestingly, glucocorticoids have been an historic treatment modality for septic patients . Perhaps part of the mechanism of action involves the promotion of efferocytosis and/or functional modulation of macrophage activation state. There is evidence that clearance of apoptotic cells results in functional modulation of the macrophage phenotype to an alternative/anti-inflammatory state as part of a pro-resolving mechanism following inflammation . Although defects in efferocytosis are known to contribute to a variety of host inflammatory diseases, the role of defective efferocytosis in sepsis and/or systemic anthrax infection is less characterized.
Edema Toxin Inhibits Efferocytosis
Given the important role of efferocytosis in regulating host inflammation, our article asked whether ET, a factor known to contribute to systemic pathology during inhalational anthrax, alters the capacity of macrophages to perform efferocytosis . To summarize these findings, primary human macrophages treated with dexamethasone developed a pro-efferocytic M2 phenotype, noted by increased expression of MerTK, CD163, CD206, and αVβ5. We found that macrophages exposed to ET in vitro at physiologically-relevant concentrations had a reduced capacity to clear apoptotic neutrophils. Further, we found that ET induced changes to the cytoskeletal machinery responsible for engulfing apoptotic cells, including focal adhesion kinase (FAK), Calmodulin-dependent protein kinases K1, K4 (CamK1, K4), vasodilator-stimulated phosphoprotein (VASP), and Rac1, which act to regulate actin organization for cell engulfment. Understanding the mechanisms whereby ET, and possibly other bacterial factors, contribute to defective efferocytosis could pave the way for new treatment strategies in late-stage anthrax and other septic infections. Intriguingly, another bacterial factor, Ba peptidoglycan, induces many key clinical markers of systemic host pathology, including vascular occlusion, organ damage, and disseminated intravascular coagulation (DIC) in baboon  and rat  models of
anthrax, suggesting that ET may not be the only bacterial
factor affecting efferocytosis during infection.
Defects in Efferocytosis are Linked to Sepsis
Despite being a defined disease process for over 3,000 years, there is no approved biologic therapy for the treatment of sepsis, with over 150 clinical trials failing to-date, suggesting an incomplete understanding of the pathology behind the septic disease process [29,30]. Preventing immune cell apoptosis is a well-described treatment strategy for sepsis ; However, studies addressing apoptotic cell clearance during sepsis, or in inhalational anthrax are few [12,32,33]. The molecular mechanisms leading to an accumulation of apoptotic lymphocytes in sepsis or the role uncleared apoptotic cells may play in sepsis progression are unclear . Under steady-state conditions, apoptotic cells are rarely detected, even in organs with high turn-over of cells such as the spleen, due to efficient clearance . This is in contrast to sepsis, where apoptotic lymphocytes and other apoptotic cell populations are detectable or abundant in the spleen, lungs, kidneys, and other organs , indicating a reduction of their clearance . Defects in the clearance of apoptotic cells permit their progression into secondary necrosis and release of intracellular pro-inflammatory DAMPs . Interestingly, levels of circulating DAMPs are known to perpetuate host organ damage in sepsis [39,40] and are implicated in causing defective efferocytosis  (Figure 1). Nucleosomes are a host-derived DAMP thought to be released from uncleared apoptotic cells. Circulating levels of nucleosomes have been shown to correlate with key features of sepsis, including intra-alveolar hemorrhage and the presence of micro-thrombi in an E. coli baboon sepsis model . In addition to host DAMPs, PAMPs such as Ba peptidoglycan have been shown to model similar features of sepsis  and modulate host immune cells [43,44]. Multiple animal models of sepsis
have demonstrated that maintaining and/or increasing
receptors (Stabilin-1 ) or soluble mediators (Gas6
, pro-efferocytic lipids , or thrombospondin )
that promote efferocytosis improves survival and reduces
negative outcomes. Whether this is an effective strategy in
inhalational anthrax remains to be investigated.
Common Features of Anthrax- and Nonanthrax Mediated Sepsis
Sepsis is a leading cause of mortality worldwide, contributing approximately 5 million deaths globally each year with nearly half due to gram positive bacteria (~48%) . Pathology of sepsis infection is complex, with often multiple contributors including bacterial PAMPs (LPS, LTA, PGN), and host-derived DAMPs (HMGB1, S100A proteins), and coagulopathies which culminate in multiple organ dysfunction syndrome and death [29,50].
Anthrax-mediated sepsis differs from other more common forms of sepsis in that its infection course is established.
Briefly, inhaled spores get transported to the mediastinal
lymph nodes, germinate, and rapidly disseminate in the
blood stream to high numbers . The major role of
Ba’s virulence factors, the outer poly-D-glutamic acid
capsule, LT and ET, are to inhibit the initial host immune
response, allowing the bacteria to multiply unimpeded
. In animal models addressing the role of toxins, they
appear to exert differential effects that are largely modeldependent.
Toxin contribution to late-stage infection,
particularly in context of anti-toxin administration
remains unclear [53,54]. PAMPs and DAMPs are likely to
contribute to defective efferocytosis in anthrax-mediated
sepsis, however, the addition of ET, which further reduces
apoptotic cell clearance, may contribute to its particularly
severe and rapid infection. Ba is an obligate pathogen,
with near 100% fatality if untreated in otherwise healthy
individuals . In contrast, other infectious agents such
as pseudomonas are usually not pathogenic for healthy
individuals and plague those who are hospitalized for other illnesses, with hospital-acquired sepsis accounting
for nearly 50% of sepsis cases . There are likely other
PAMPs shared across organisms, as well as host DAMPs
in addition to ET that contribute to defective efferocytosis.
Regardless of the route or causative agent there appears
to be underlying disease mechanisms in common for
both anthrax- and non-anthrax mediated sepsis once the
bacteria are fulminant.
Efferocytosis May Help or Harm the Host during Infection
While defective efferocytosis may be a feature of severe sepsis, how its modulation may impact late-stage infection is unclear. Currently, the literature is mixed and contextdependent, with some studies indicating that efferocytosis may increase the risk of infection due to immune suppression (e.g. higher TGF-beta, IL-10) [56,57], while others show increased bacterial clearance [58,59]. Data from in vitro modeling of how tissue-resident macrophages respond to diverse stimuli including bacterial PAMPs and apoptotic cells are also inconsistent due to differences in the studied macrophage sub-types, stimuli, and experimental methodologies [26,60-62]. One treatment paradigm currently being developed (Allocetra) aims to polarize macrophages to an alternative/pro-efferocytic phenotype by allogeneic apoptotic cell therapy. In a mouse cecal ligation and puncture model, in which affected mice exhibit sepsis with multiple organ dysfunction syndromes, severe cytokine storm, and acute kidney injury, Allocetra in combination with the antibiotic ertapenem, reduced disease severity by 50%, and improved survival by 10-fold (6% vs 60%) .
Conclusion and Perspectives
Large increases in apoptotic cells are a known feature common to sepsis and inhalational anthrax. Prior treatment strategies have been aimed primarily at combating infection, blocking excessive host inflammation, and preventing host cell apoptosis. Emerging studies suggest that harnessing the efferocytic and pro-resolving activities of endogenous macrophages may be another tool in the arsenal for treating sepsis and reducing mortality. We found that ET reduced efferocytosis, and altered cytoskeletal signaling in human macrophages. ET, combined with other bacterial factors and host DAMPs, act to inhibit efferocytosis and augment host inflammation. Prior work from other labs demonstrate bacterial components, namely LPS, or host-derived DAMPs can reduce efferocytic capacity in a potential feed-forward loop. However, whether other bacterial and/or host-derived factors affect this process and which inhibitory factors predominate during infection, are yet to be investigated. Work on multiple fronts suggest that modulating efferocytosis could reduce negative outcomes in sepsis, including reducing the systemic inflammatory response and host mortality in animal sepsis models. Based on current literature, sepsis from various bacterial origins appear to maintain common underlying disease mechanism(s), in part manifested as an elevation in inflammatory cytokines, defects in apoptotic cell clearance, organ damage and high mortality. Thus, we hope to shed light on this topic to stimulate further research exploring efferocytosis in sepsis and systemic anthrax infection.
Author Contributions Statement
JSM wrote the manuscript. JSM, ZP, ADF edited the
manuscript. All authors approved the final version.
This work was supported by the National Institute of Allergy and Infectious Diseases Cooperative Centers for Human Immunology grant U19AI062629. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The authors declare no conflicts of interest or disclosures.
- Goel AK. Anthrax: A disease of biowarfare and public
health importance. World J Clin Cases. 2015;3(1):20-33.
- Dixon TC, Meselson M, Guillemin J, Hanna PC.
Anthrax. N Engl J Med. 1999;341(11):815-26.
- Johari MR. Anthrax - Biological Threat in the 21(st)
Century. Malays J Med Sci. 2002;9(1):1-2.
- Singer M, Deutschman CS, Seymour CW, Shankar-
Hari M, Annane D, Bauer M, et al. The Third International
Consensus Definitions for Sepsis and Septic Shock
(Sepsis-3). JAMA. 2016;315(8):801-10.
- Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James
JA, Farris D, et al. The sepsis model: an emerging
hypothesis for the lethality of inhalation anthrax. J Cell
Mol Med. 2013;17(7):914-20.
- Cheng Z, Abrams ST, Toh J, Wang SS, Wang Z, Yu Q,
et al. The Critical Roles and Mechanisms of Immune Cell
Death in Sepsis. Front Immunol. 2020;11:1918.
- Patel VI, Booth JL, Dozmorov M, Brown BR, Metcalf
JP. Anthrax Edema and Lethal Toxins Differentially Target Human Lung and Blood Phagocytes. Toxins (Basel).
- Wu W, Mehta H, Chakrabarty K, Booth JL, Duggan
ES, Patel KB, et al. Resistance of human alveolar
macrophages to Bacillus anthracis lethal toxin. J Immunol.
- Fang H, Cordoba-Rodriguez R, Lankford CS,
Frucht DM. Anthrax lethal toxin blocks MAPK kinasedependent
IL-2 production in CD4+ T cells. J Immunol.
- Fang H, Xu L, Chen TY, Cyr JM, Frucht DM. Anthrax
lethal toxin has direct and potent inhibitory effects on
B cell proliferation and immunoglobulin production. J
- During RL, Li W, Hao B, Koenig JM, Stephens DS,
Quinn CP, et al. Anthrax lethal toxin paralyzes neutrophil
actin-based motility. J Infect Dis. 2005;192(5):837-45.
- Cao C, Yu M, Chai Y. Pathological alteration and
therapeutic implications of sepsis-induced immune cell
apoptosis. Cell Death Dis. 2019;10(10):782.
- Silva MT. Secondary necrosis: the natural outcome
of the complete apoptotic program. FEBS Lett.
- Amarante-Mendes GP, Adjemian S, Branco LM,
Zanetti LC, Weinlich R, Bortoluci KR. Pattern Recognition
Receptors and the Host Cell Death Molecular Machinery.
Front Immunol. 2018;9:2379.
- Liu S, Moayeri M, Leppla SH. Anthrax lethal and
edema toxins in anthrax pathogenesis. Trends Microbiol.
- Stearns-Kurosawa DJ, Lupu F, Taylor FB, Jr.,
Kinasewitz G, Kurosawa S. Sepsis and pathophysiology
of anthrax in a nonhuman primate model. Am J Pathol.
- Yeager LA, Chopra AK, Peterson JW. Bacillus anthracis
edema toxin suppresses human macrophage phagocytosis
and cytoskeletal remodeling via the protein kinase A and
exchange protein activated by cyclic AMP pathways. Infect
- Rossi Paccani S, Tonello F, Patrussi L, Capitani N,
Simonato M, Montecucco C, et al. Anthrax toxins inhibit
immune cell chemotaxis by perturbing chemokine receptor
signalling. Cell Microbiol. 2007;9(4):924-9.
- Abdolmaleki F, Farahani N, Gheibi Hayat SM, Pirro
M, Bianconi V, Barreto GE, et al. The Role of Efferocytosis in Autoimmune Diseases. Front Immunol. 2018;9:1645.
- Mahida R, Thickett D. Impaired Alveolar Macrophage
Efferocytosis in ARDS causes accumulation of apoptotic
neutrophils & prolonged inflammation. European
Respiratory Journal. 2018;52(suppl 62):PA4283.
- Kourtzelis I, Li X, Mitroulis I, Grosser D, Kajikawa T,
Wang B, et al. DEL-1 promotes macrophage efferocytosis
and clearance of inflammation. Nat Immunol.
- Boada-Romero E, Martinez J, Heckmann BL, Green
DR. The clearance of dead cells by efferocytosis. Nat Rev
Mol Cell Biol. 2020;21(7):398-414.
- Baratin M, Simon L, Jorquera A, Ghigo C, Dembele D,
Nowak J, et al. T Cell Zone Resident Macrophages Silently
Dispose of Apoptotic Cells in the Lymph Node. Immunity.
- Roberts AW, Lee BL, Deguine J, John S, Shlomchik
MJ, Barton GM. Tissue-Resident Macrophages Are
Locally Programmed for Silent Clearance of Apoptotic
Cells. Immunity. 2017;47(5):913-27 e6.
- Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient
clearance of early apoptotic cells by human macrophages
requires M2c polarization and MerTK induction. J
- Gharib SA, McMahan RS, Eddy WE, Long ME, Parks
WC, Aitken ML, et al. Transcriptional and functional
diversity of human macrophage repolarization. J Allergy
Clin Immunol. 2019;143(4):1536-48.
- Vandewalle J, Libert C. Glucocorticoids in Sepsis: To
Be or Not to Be. Front Immunol. 2020;11:1318.
- Pan Z, Dumas EK, Lawrence C, Pate L, Longobardi
S, Wang X, et al. Bacillus anthracis Edema Toxin
Inhibits Efferocytosis in Human Macrophages and Alters
Efferocytic Receptor Signaling. Int J Mol Sci. 2019;20(5).
- Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K,
Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev
Dis Primers. 2016;2:16045.
- Marshall JC. Why have clinical trials in sepsis failed?
Trends Mol Med. 2014;20(4):195-203.
- Cheng ZX, Abrams ST, Toh J, Wang SS, Wang Z, Yu Q,
et al. The Critical Roles and Mechanisms of Immune Cell
Death in Sepsis. Frontiers in Immunology. 2020;11.
- Poon IK, Lucas CD, Rossi AG, Ravichandran KS.
Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol. 2014;14(3):166-80.
- Saas P, Daguindau E, Perruche S. Concise Review:
Apoptotic Cell-Based Therapies-Rationale, Preclinical
Results and Future Clinical Developments. Stem Cells.
- Drewry AM, Samra N, Skrupky LP, Fuller BM,
Compton SM, Hotchkiss RS. Persistent lymphopenia
after diagnosis of sepsis predicts mortality. Shock.
- Morioka S, Maueroder C, Ravichandran KS. Living
on the Edge: Efferocytosis at the Interface of Homeostasis
and Pathology. Immunity. 2019;50(5):1149-62.
- Bantel H, Schulze-Osthoff K. Cell death in sepsis: a
matter of how, when, and where. Crit Care. 2009;13(4):173.
- Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki
T, Winkler MS, Lachmann G, et al. Current gaps in sepsis
immunology: new opportunities for translational research.
Lancet Infect Dis. 2019;19(12):e422-e36.
- Deng MH, Scott MJ, Fan J, Billiar TR. Location is
the key to function: HMGB1 in sepsis and trauma-induced
inflammation. J Leukocyte Biol. 2019;106(1):161-9.
- Denning NL, Aziz M, Gurien SD, Wang P. DAMPs and
NETs in Sepsis. Front Immunol. 2019;10:2536.
- Sharma SK, Naidu G. The role of danger-associated
molecular patterns (DAMPs) in trauma and infections. J
Thorac Dis. 2016;8(7):1406-9.
- Xu J, Zhang X, Pelayo R, Monestier M, Ammollo
CT, Semeraro F, et al. Extracellular histones are major
mediators of death in sepsis. Nat Med. 2009;15(11):1318-
- Sun D, Raisley B, Langer M, Iyer JK, Vedham V,
Ballard JL, et al. Anti-peptidoglycan antibodies and
Fcgamma receptors are the key mediators of inflammation
in Gram-positive sepsis. J Immunol. 2012;189(5):2423-
- Popescu NI, Girton A, Burgett T, Lovelady K,
Coggeshall KM. Monocyte procoagulant responses to
anthrax peptidoglycan are reinforced by proinflammatory
cytokine signaling. Blood Adv. 2019;3(16):2436-47.
- Popescu NI, Keshari RS, Cochran J, Coggeshall
KM, Lupu F. C3 Opsonization of Anthrax Bacterium and
Peptidoglycan Supports Recognition and Activation of
Neutrophils. Microorganisms. 2020;8(7).
- Lee W, Park SY, Yoo Y, Kim SY, Kim JE, Kim SW, et al. Macrophagic Stabilin-1 Restored Disruption of Vascular Integrity Caused by Sepsis. Thromb Haemost. 2018;118(10):1776-89.
- Ni J, Lin M, Jin Y, Li J, Guo Y, Zhou J, et al. Gas6
Attenuates Sepsis-Induced Tight Junction Injury and
Vascular Endothelial Hyperpermeability via the Axl/NFkappaB
Signaling Pathway. Front Pharmacol. 2019;10:662.
- Korner A, Schlegel M, Theurer J, Frohnmeyer H,
Adolph M, Heijink M, et al. Resolution of inflammation
and sepsis survival are improved by dietary Omega-3 fatty
acids. Cell Death Differ. 2018;25(2):421-31.
- Akatsuka M, Masuda Y, Tatsumi H, Yamakage
M. Recombinant human soluble thrombomodulin is
associated with attenuation of sepsis-induced renal
impairment by inhibition of extracellular histone release.
Plos One. 2020;15(1):e0228093.
- Dolin HH, Papadimos TJ, Chen X, Pan ZK.
Characterization of Pathogenic Sepsis Etiologies and
Patient Profiles: A Novel Approach to Triage and Treatment.
Microbiol Insights. 2019;12:1178636118825081.
- Lelubre C, Vincent JL. Mechanisms and treatment of
organ failure in sepsis. Nat Rev Nephrol. 2018;14(7):417-
- Savransky V, Ionin B, Reece J. Current Status and
Trends in Prophylaxis and Management of Anthrax
Disease. Pathogens. 2020;9(5).
- Cote CK, Welkos SL. Anthrax Toxins in Context of
Bacillus anthracis Spores and Spore Germination. Toxins
- Tournier JN, Rougeaux C, Biot FV, Goossens PL.
Questionable Efficacy of Therapeutic Antibodies in the
Treatment of Anthrax. mSphere. 2019;4(3).
- Huang E, Pillai SK, Bower WA, Hendricks KA,
Guarnizo JT, Hoyle JD, et al. Antitoxin Treatment of
Inhalation Anthrax: A Systematic Review. Health Secur.
- Twenhafel NA. Pathology of inhalational anthrax
animal models. Vet Pathol. 2010;47(5):819-30.
- Karaji N, Sattentau QJ. Efferocytosis of Pathogen-
Infected Cells. Front Immunol. 2017;8:1863.
- Benoit M, Desnues B, Mege JL. Macrophage
polarization in bacterial infections. J Immunol.
- Martin CJ, Booty MG, Rosebrock TR, Nunes Alves C, Desjardins DM, Keren I, et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe. 2012;12(3):289-300.
- Greenlee-Wacker MC, Rigby KM, Kobayashi SD,
Porter AR, DeLeo FR, Nauseef WM. Phagocytosis of
Staphylococcus aureus by human neutrophils prevents
macrophage efferocytosis and induces programmed
necrosis. J Immunol. 2014;192(10):4709-17.
- Roszer T. Understanding the Mysterious M2
Macrophage through Activation Markers and Effector
Mechanisms. Mediators Inflamm. 2015;2015:816460.
- Abdelaziz MH, Abdelwahab SF, Wan J, Cai W, Huixuan
W, Jianjun C, et al. Alternatively activated macrophages;
a double-edged sword in allergic asthma. J Transl Med.
- Viola A, Munari F, Sanchez-Rodriguez R, Scolaro
T, Castegna A. The Metabolic Signature of Macrophage
Responses. Front Immunol. 2019;10:1462.
- Karbian N, Abutbul A, El-Amore R, Eliaz R, Beeri
R, Reicher B, et al. Apoptotic cell therapy for cytokine
storm associated with acute severe sepsis. Cell Death Dis.